Concepedia

Damon Jack

DJ

Statistics

Publications

6

Citations

682

H-Index

6

Active since

2006

Affiliations

Novartis (United States)(Current)

Novartis (United Kingdom)

Novartis (Switzerland)

Johannes Gutenberg University Mainz

Hôpital Arnaud de Villeneuve

Damon Jack is an author at Novartis (United States) specializing in obstructive lung disease, medicine, and pharmacotherapy.

Publications per year

2006–2010

6

Publications

6

Efficacy of a new once-daily long-acting inhaled  2-agonist indacaterol versus twice-daily formoterol in COPD

Ronald Dahl, Kian Fan Chung, Roland Buhl et al. · Thorax · 2010 · 274 citations · Full text

, , +17

Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

Gregory Feldman, Thomas M. Siler, Niyati Prasad et al. · BMC Pulmonary Medicine · 2010 · 119 citations · Full text

, , +17

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison

Stephen I. Rennard, Theo A. Bantje, Stefano Centanni et al. · Respiratory Medicine · 2008 · 89 citations · Full text

, , +11

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium

Claus Vogelmeier, David Ramos‐Barbón, Damon Jack et al. · Respiratory Research · 2010 · 89 citations · Full text

, , +16

Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial

Jutta Beier, Pascal Chanez, Jean‐Benoît Martinot et al. · Pulmonary Pharmacology & Therapeutics · 2006 · 83 citations · Full text

, , +11

1–5 of 6